Gefitinib encapsulation based on nano-liposomes for enhancing the curative effect of lung cancer

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.
   PubMed Web of Science ®Google Scholar
• Liu Q, Bai W, Huang F, et al. Downregulation of microRNA-196a inhibits stem cell self-renewal ability and stemness in non-small-cell lung cancer through upregulating GPX3 expression. Int J Biochem Cell Biol. 2019;115:105571.
   PubMed Web of Science ®Google Scholar
• Raez LE, Cardona AF, Santos ES, et al. The burden of lung cancer in Latin-America and challenges in the access to genomic profiling, immunotherapy and targeted treatments. Lung Cancer. 2018;119:7–13.
   PubMed Web of Science ®Google Scholar
• Deng Q, Fang Q, Xie B, et al. Exosomal long non-coding RNA MSTRG.292666.16 is associated with osimertinib (AZD9291) resistance in non-small cell lung cancer. Aging (Albany NY). 2020;12(9):8001–8015.
   PubMedGoogle Scholar
• Dijkstra KK, Monkhorst K, Schipper LJ, et al. Challenges in establishing pure lung cancer organoids limit their utility for personalized medicine. Cell Rep. 2020;31(5):107588.
   PubMed Web of Science ®Google Scholar
• Liu D, Cao Z, Xu W, et al. Enhancement of chemosensitivity by WEE1 inhibition in EGFR-TKIs resistant non-small cell lung cancer. Biomed Pharmacothe. 2019;117:109185.
   PubMed Web of Science ®Google Scholar
• Gala UH, Miller DA, Williams RO 3rd. Harnessing the therapeutic potential of anticancer drugs through amorphous solid dispersions. Biochim Biophys Acta Bioenerg Reviews on Cancer. 2020;1873:188319.
   PubMed Web of Science ®Google Scholar
• Park K. Controlled drug delivery systems: past forward and future back. J Control Release. 2014;190:3–8.
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhao Q, Han N, et al. Mesoporous silica nanoparticles in drug delivery and biomedical applications. Nanomedicine. 2015;11(2):313–327.
   PubMed Web of Science ®Google Scholar
• Karthivashan G, Ganesan P, Park SY, et al. Therapeutic strategies and nano-drug delivery applications in management of ageing Alzheimer’s disease. Drug Deliv. 2018;25:307–320.
   PubMed Web of Science ®Google Scholar
• Shen J, Lu GW, Hughes P. Targeted ocular drug delivery with pharmacokinetic/pharmacodynamic considerations. Pharm Res. 2018;35:217.
   PubMed Web of Science ®Google Scholar
• Roskoski R Jr. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers. Pharmacol Res. 2019;139:395–411.
   PubMed Web of Science ®Google Scholar
• Supuran CT. Carbonic anhydrase inhibitors as emerging agents for the treatment and imaging of hypoxic tumors. Expert Opin Investig Drugs. 2018;27:963–970.
   PubMed Web of Science ®Google Scholar
• Cheng Y, Qi Y. Current progresses in metal-based anticancer complexes as mammalian TrxR inhibitors. Anticancer Agents Med Chem. 2017;17:1046–1069.
   PubMed Web of Science ®Google Scholar
• Sidera K, Patsavoudi E. HSP90 inhibitors: current development and potential in cancer therapy. Recent Pat Anticancer Drug Discov. 2014;9:1–20.
   PubMed Web of Science ®Google Scholar
• Häntschel M, Niebling J, Häring A, et al. Life-threatening pneumonitis after first-line treatment with osimertinib for primary T790M mutated non-small cell lung cancer. Thorac Cancer. 2020;11(7):2044–2047.
   PubMed Web of Science ®Google Scholar
• Sari M, Aydiner A. Rare mutations of epidermal growth factor receptor in epidermal growth factor receptor-tyrosine kinase inhibitor-naive non-small cell lung carcinoma and the response to erlotinib therapy. J Cancer Res Ther. 2020;16:132–138.
   PubMed Web of Science ®Google Scholar
• Alam MW, Borenäs M, Lind DE, et al. Alectinib, an anaplastic lymphoma kinase inhibitor, abolishes ALK activity and growth in ALK-positive neuroblastoma cells. Front Oncol. 2019;9:579.
   PubMed Web of Science ®Google Scholar
• Sun Z, Zeng L, Zhang M, et al. PIM1 inhibitor synergizes the anti-tumor effect of osimertinib via STAT3 dephosphorylation in EGFR-mutant non-small cell lung cancer. Ann Transl Med. 2020;8(6):366.
   PubMed Web of Science ®Google Scholar
• Yang JC-H, Cheng Y, Murakami H, et al. A randomized phase 2 study of gefitinib with or without pemetrexed as first-line treatment in nonsquamous NSCLC With EGFR mutation: final overall survival and biomarker analysis. J Thorac Oncol. 2020;15(1):91–100.
   PubMed Web of Science ®Google Scholar
• Lai K-C, Chueh F-S, Hsiao Y-T, et al. Gefitinib and curcumin-loaded nanoparticles enhance cell apoptosis in human oral cancer SAS cells in vitro and inhibit SAS cell xenografted tumor in vivo. Toxicol Appl Pharmacol. 2019;382:114734.
   PubMed Web of Science ®Google Scholar
• Shariati A, Habibi M, Tounsi A, et al. Application of exact continuum size-dependent theory for stability and frequency analysis of a curved cantilevered microtubule by considering viscoelastic properties. 2020;1–20.
   Google Scholar
• Zhang X, Shamsodin M, Wang H, et al. Dynamic information of the time-dependent tobullian biomolecular structure using a high-accuracy size-dependent theory. J Biomol Struct Dyn. 2020;1–16. DOI:10.1080/07391102.2020.1760939
   PubMed Web of Science ®Google Scholar
• Najaafi N, Jamali M, Habibi M, et al. Dynamic instability responses of the substructure living biological cells in the cytoplasm environment using stress-strain size-dependent theory. J Biomol Struct Dyn. 2020;1–12. DOI:10.1080/07391102.2020.1751297
   Web of Science ®Google Scholar
• Abdelmalek Z, Karbon M, Eyvazian A, et al. On the dynamics of a curved microtubule-associated proteins by considering viscoelastic properties of the living biological cells. J Biomol Struct Dyn. 2020;1–15. DOI:10.1080/07391102.2020.1747549
   Web of Science ®Google Scholar
• Zhang P, Ge Z, Safarpour M. Size-dependent dynamic stability analysis of the cantilevered curved microtubule-associated proteins (MAPs). J Biomol Struct Dyn. 2020;1–13. DOI:10.1080/07391102.2020.1758211
   PubMed Web of Science ®Google Scholar
• Tang M, Svirskis D, Leung E, et al. Can intracellular drug delivery using hyaluronic acid functionalised pH-sensitive liposomes overcome gemcitabine resistance in pancreatic cancer? J Control Release. 2019;305:89–100.
   PubMed Web of Science ®Google Scholar
• Kahana M, Weizman A, Gabay M, et al. Liposome-based targeting of dopamine to the brain: a novel approach for the treatment of Parkinson’s disease. Mol Psychiatry. 2020. DOI:10.1038/s41380-020-0742-4
   PubMed Web of Science ®Google Scholar
• Dharmaraj K, Román Silva JI, Kahlert H, et al. The acid-base and redox properties of menaquinone MK-4, MK-7, and MK-9 (vitamin K(2)) in DMPC monolayers on mercury. Eur Biophys J. 2020;49:279–288.
   PubMed Web of Science ®Google Scholar
• Yang B, Chen Y, Tumor-Specific SJ. Chemotherapy by nanomedicine-enabled differential stress sensitization. Angew Chem Int Ed Engl. 2020;59:9693–9701.
   PubMed Web of Science ®Google Scholar
• Elnaggar YSR, Omran S, Hazzah HA, et al. Anionic versus cationic bilosomes as oral nanocarriers for enhanced delivery of the hydrophilic drug risedronate. Int J Pharm. 2019;564:410–425.
   PubMed Web of Science ®Google Scholar
• Yu L-M, Liu Y-L, Zhu L-B, et al. Boosting the biocatalytic precipitation with enzyme-loaded liposomes: toward a general platform for amplified photoelectrochemical immunoassay. Anal Chim Acta. 2020;1115:1–6.
   PubMed Web of Science ®Google Scholar
• Zhi LJ, Sun AL, Tang D. In situ amplified photothermal immunoassay for neuron-specific enolase with enhanced sensitivity using Prussian blue nanoparticle-loaded liposomes. Analyst. 2020;145:4164–4172.
   PubMed Web of Science ®Google Scholar
• Zhang X, Liu Y, Luo L, et al. A chemo-photothermal synergetic antitumor drug delivery system: gold nanoshell coated wedelolactone liposome. Mater Sci Eng C Mater Biol Appl. 2019;101:505–512.
   PubMed Web of Science ®Google Scholar
• de Freitas CF, Montanha MC, Pellosi DS, et al. Biotin-targeted mixed liposomes: a smart strategy for selective release of a photosensitizer agent in cancer cells. Mater Sci Eng C Mater Biol Appl. 2019;104:109923.
   PubMed Web of Science ®Google Scholar
• Zhou C, Xie X, Yang H, et al. Novel class of ultrasound-triggerable drug delivery systems for the improved treatment of tumors. Mol Pharm. 2019;16(7):2956–2965.
   PubMedGoogle Scholar
• Dianat-Moghadam H, Heidarifard M, Jahanban-Esfahlan R, et al. Cancer stem cells-emanated therapy resistance: implications for liposomal drug delivery systems. J Control Release. 2018;288:62–83.
   PubMed Web of Science ®Google Scholar
• Chen L, Cheng X, Tu W, et al. Apatinib inhibits glycolysis by suppressing the VEGFR2/AKT1/SOX5/GLUT4 signaling pathway in ovarian cancer cells. Cell Oncol (Dordr). 2019;42(5):679–690.
   PubMed Web of Science ®Google Scholar
• Yu M, Song W, Tian F, et al. Temperature- and rigidity-mediated rapid transport of lipid nanovesicles in hydrogels. Proc Natl Acad Sci U S A. 2019;116(12):5362–5369.
   PubMed Web of Science ®Google Scholar
• Tian T, Zhang H-X, He C-P, et al. Surface functionalized exosomes as targeted drug delivery vehicles for cerebral ischemia therapy. Biomaterials. 2018;150:137–149.
   PubMed Web of Science ®Google Scholar